Pharma News
01 Jun 2025 to 07 Jun 2025
Jun 7, 2025
Pfizer's strong competitive advantage is bolstered by patents and economies of scale - Yahoo Finance
President Trump is expected to announce significant tariffs on pharmaceutical products, potentially impacting the biopharma industry, particularly Pfizer, which may face a 25% tariff on European imports. Additionally, Trump's executive order aims to reduce U.S. drug prices by aligning them with the lowest international rates, which could significantly affect Pfizer's revenue from high-margin medications.
Jun 7, 2025
Transforming generics to international research and development: The impact of India's patent legislation on its pharmaceutical sector.
The Indian pharmaceutical industry has surged to $50 billion in 2023-24, up from $8 billion in 2005-06, driven by domestic consumption and exports. Regulatory improvements, including new drug and clinical trial rules, have fostered innovation, according to A. K. Pradhan from the Central Drugs Standards Control Organisation (CDSCO). India is now the world's third-largest drug producer by volume.
Jun 7, 2025
Eli Lilly's Mounjaro Sales Surge by 60% in India, Indicating Strong Presence in Emerging Obesity Market
Eli Lilly's Mounjaro (tirzepatide) has seen a remarkable 60% sales increase in India, reaching ₹126 million ($1.5 million) in May, its first full month on the market. The drug's success is attributed to strong demand and strategic pricing, establishing Eli Lilly's first-mover advantage in India's growing obesity and diabetes treatment market.
Jun 6, 2025
Addressing Elevated Medication Costs Necessitates Changes to Patent Laws, According to R Street Institute
President Trump’s recent executive order aims to address high prescription drug prices, highlighting the need for patent reforms in the pharmaceutical sector. Companies like AbbVie, with its drug Humira (adalimumab), exploit patent systems to maintain high prices. Legislative efforts, such as the Affordable Prescriptions for Patients Act, seek to limit patent abuses and enhance competition, but challenges remain in reforming patent policies.
Jun 6, 2025
Our goal was to measure the impact of U.S. academia on medical advancements, and the findings surprised us greatly.
A recent study reveals that American universities contributed patents for 50% of FDA-approved drugs from 2020 to 2024, with 87% of these breakthroughs originating from U.S. institutions. This highlights the critical role of academic research in pharmaceutical innovation, as companies like Merck and Bayer increasingly rely on university inventors. Continued federal support is essential to maintain U.S. leadership in drug development.
Jun 6, 2025
Stony Brook Officials Emphasize the Crucial Contribution of U.S. Universities to Drug Development in an Op-Ed
A new op-ed by Kevin Gardner and Michael Kinch highlights the crucial role of U.S. universities in drug development, revealing they contributed key patents for half of all FDA-approved drugs from 2020 to 2024. They stress the need for continued federal investment in academic research to maintain innovation and address global competition, particularly from China.
Jun 5, 2025
Robert Holton, a key figure in the creation of a powerful cancer medication, has passed away at the age of 81 - The Washington Post.
Robert Holton, a chemist who developed a cost-efficient method for producing the cancer drug Taxol, passed away at 81. Taxol, effective against various cancers, has treated over a million patients. Holton's synthesis techniques, licensed to Bristol Myers Squibb, revolutionized its production, leading to FDA approvals in the early 1990s. His contributions significantly advanced cancer treatment.
Jun 5, 2025
Dr. Reddy's and Alvotech to collaborate on the development of a biosimilar for Keytruda - The Economic Times
Dr Reddy’s Laboratories has partnered with Alvotech to co-develop a biosimilar of Keytruda (pembrolizumab), a leading cancer treatment by Merck & Co. This collaboration aims to enhance access to affordable cancer therapies globally, particularly as Merck's patents are set to expire around 2028. Keytruda is approved for multiple cancers, with high costs limiting access in India.
Jun 5, 2025
Dr. Reddy's and Alvotech collaborate to jointly develop, produce, and market a biosimilar of ...
Dr Reddy’s Laboratories has partnered with Alvotech to co-develop, manufacture, and commercialize a biosimilar of Merck's Keytruda (pembrolizumab), a leading cancer treatment with over $29.5 billion in sales. The collaboration aims to expedite development and expand global access to affordable biologic medications, enhancing both companies' capabilities in oncology.
Jun 5, 2025
Women using popular weight loss medications advised to employ reliable birth control methods.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) warns pregnant and breastfeeding women against using weight loss drugs like Mounjaro, Ozempic, and Wegovy due to insufficient safety data. The agency emphasizes the importance of effective contraception while using these GLP-1 receptor agonists, which are intended for treating obesity and type 2 diabetes, not for cosmetic purposes.
Jun 5, 2025
Dr. Reddy's Laboratories sees a 4% rise in stock, becoming the leading gainer on Nifty following a biosimilar agreement with Alvotech.
Dr. Reddy’s Laboratories shares rose 4% to Rs 1,303 following a collaboration with Alvotech to develop a biosimilar of Keytruda (pembrolizumab). HSBC upgraded the stock to ‘Buy’ and raised its target price, citing potential growth from Semaglutide for type-2 diabetes in key markets like Canada, Brazil, and India. The stock has gained 9% in the past month.
Jun 5, 2025
Investors Show Optimism Over Dr Reddy's Partnership with Alvotech - The New Indian Express
Dr Reddy’s Laboratories shares rose over 3% following a global licensing agreement with Iceland's Alvotech to co-develop a biosimilar candidate for Keytruda (pembrolizumab), a leading cancer immunotherapy by Merck & Co. This partnership enhances Dr Reddy's biosimilars pipeline and aims to strengthen its position in the global oncology market.
Jun 5, 2025
From breakthrough to blockbuster: Seed funding propels transformative scientific advancements | WEHI
Researchers at WEHI Ventures are developing a groundbreaking therapy for Prader-Willi Syndrome (PWS), a rare neurodevelopmental disorder. The focus is on targeting the protein SMCHD1 to activate genes that could treat PWS symptoms. This innovative approach, led by a team including venture principal scientist Nick, aims to improve the lives of hundreds of thousands of patients worldwide.
Jun 5, 2025
MHRA Advises Women on GLP-1 Weight-Loss Medications to Employ Contraceptive Methods Due to ...
The MHRA has warned women using GLP-1 weight-loss drugs to ensure effective contraception due to pregnancy risks. The agency highlighted concerns over unregulated access to these medications, which may lack critical safety information. GLP-1 receptor agonists are not recommended for pregnant women due to potential adverse effects on fetal development.
Jun 5, 2025
Dr. Reddy's Laboratories Sees 4% Increase in Stock Following Agreement with Alvotech for Biosimilar Development
Dr Reddy’s is eyeing a blockbuster opportunity with Pembrolizumab, which generated $29.5 billion in global sales in 2024. This move could help offset anticipated revenue losses from Revlimid, another major cancer drug set to go off-patent in 2026, which has been a key growth driver for the company.
Jun 5, 2025
Authorities in Malakpet have confiscated four suspected counterfeit medications valued at Rs. 5.21 lakhs, according to Drugs Control officials.
Authorities in Hyderabad seized four suspected spurious drugs valued at Rs. 5.21 lakhs during a raid on June 4, 2025, at the residence of Puvvada Lakshmana in Malakpet. The operation was conducted by special teams following credible information about illegal drug procurement from an unlicensed location.
Jun 5, 2025
Bayer's Nubeqa gains FDA approval in the US for individuals with advanced prostate cancer.
Bayer's Nubeqa (darolutamide) has received FDA approval for use with androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The approval follows positive results from the Phase III ARANOTE trial, showing a 46% reduction in radiological progression or death. Nubeqa is also approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and has achieved blockbuster status.
Jun 5, 2025
Examining Pharmaceutical Patents and Investigating Policies for Generic Medications - LSE Blogs
Professor Ken Shadlen recently visited Mexico City to present research on pharmaceutical patent linkage and generic drug regulation. His study focuses on the impact of Mexico's linkage system on the acquisition of HIV medicines, particularly how it affects costs and access to generics. The research aims to quantify excess expenditures incurred by Mexico's HIV/AIDS agency due to this system.
Jun 5, 2025
J&J's Approach to Lung Cancer Growth Draws on Its Expertise in Multiple Myeloma
Johnson & Johnson (J&J) is expanding its lung cancer pipeline, leveraging its experience in multiple myeloma, particularly with its top-selling drug Darzalex. J&J's Rybrevant, a bispecific antibody, recently received full FDA approval for first-line treatment of EGFR-mutated non-small cell lung cancer. The company also aims to enhance Rybrevant's delivery with a subcutaneous version and explore its use in other cancers.
Jun 5, 2025
Merck & Co. (MRK) Shares Decline on NYSE, Continuing Recent Slide Despite Robust All...
Merck & Company, Inc. (MRK) shares fell 0.64% today, closing at 77.77 USD on the NYSE. This decline is part of a broader negative trend, with the stock down 39.51% over the past year. Despite recent challenges, Merck remains a leader in healthcare, known for its innovative products like the cancer drug Keytruda.
Jun 5, 2025
MAIA Biotechnology's Investigational Cancer Treatment Demonstrates Threefold Increase in Survival Compared to ... - Yahoo Finance
MAIA Biotechnology, Inc. announced promising results from its THIO-101 Phase 2 trial, showing a median overall survival of 17.8 months for advanced non-small cell lung cancer patients treated with ateganosine (THIO) and Regeneron's cemiplimab (Libtayo). This survival rate is nearly triple that of standard chemotherapy. The treatment has been well-tolerated, with potential for accelerated FDA approval.
Jun 5, 2025
What is Causing MAIA Biotechnology's Stock to Rise on Thursday? - Benzinga
MAIA Biotechnology, Inc. announced promising results from its THIO-101 Phase 2 trial, showing a median overall survival of 17.8 months for advanced non-small cell lung cancer patients treated with ateganosine (THIO) and Regeneron’s cemiplimab (Libtayo). This survival rate significantly exceeds standard chemotherapy outcomes. The company anticipates potential FDA approval for ateganosine as early as next year.
Jun 5, 2025
Dr. Reddy's and Alvotech Collaborate to Create a Biosimilar for Merck's Popular Cancer Treatment
Alvotech (ALVO) has partnered with Dr. Reddy's Laboratories (RDY) to co-develop a biosimilar candidate to Merck's Keytruda (pembrolizumab) for global markets. This collaboration aims to expedite development and commercialization, sharing costs and responsibilities. Keytruda generated $29.5 billion in sales in 2024. Additionally, Dr. Reddy's stock rose 6.07% to $15.65, while Alvotech's fell 2.49% to $10.56.
Jun 4, 2025
MLTX Shares Rise 18% Amid Reports of Merck's Acquisition Interest - TradingView
Shares of MoonLake Immunotherapeutics (MLTX) surged 18% after reports that Merck (MRK) is interested in acquiring the company for over $3 billion. Although Merck's initial offer was rejected, talks may resume as the company seeks to diversify its revenue, heavily reliant on Keytruda. MoonLake is developing sonelokimab for inflammatory diseases, with data expected in 2025.
Jun 3, 2025
Merck Expands Its Acquisition Efforts with MoonLake Offer as Keytruda Patent Expiration Approaches: Report
Merck & Co Inc (MRK) has made a bid exceeding $3 billion for Swiss biotech MoonLake Immunotherapeutics (MLTX), which was initially rejected. The potential acquisition is driven by Merck's need for new assets as its cancer drug Keytruda faces patent expiration. MoonLake's lead asset, sonelokimab, targets inflammatory diseases and has seen increased investor interest.
Jun 3, 2025
Kymera's STAT6 Degrader Demonstrates Promising Results in Phase I Trials for Inflammatory Conditions
Kymera Therapeutics has reported positive Phase I trial results for KT-621, an oral drug targeting chronic inflammation and allergic reactions, including asthma and atopic dermatitis. The drug achieved over 90% STAT6 degradation and showed a safety profile similar to placebo. KT-621 aims to compete with Sanofi and Regeneron's Dupilumab, with further trials planned for 2025 and 2026.
Jun 3, 2025
Revolutionary Advances in Cancer Research May Enhance Health Results for African American Communities
At the ASCO annual meeting, AstraZeneca's Enhertu and Pfizer's Braftovi showed promising results in treating aggressive cancers, with Enhertu significantly delaying progression in HER2-positive breast cancer and Braftovi improving outcomes in BRAF-mutated colorectal cancer. Gilead's Trodelvy and Merck's Keytruda also demonstrated potential for triple-negative breast cancer. Meanwhile, Merck faced a setback with patritumab deruxtecan for lung cancer.
Jun 3, 2025
Should You Consider Buying BioNTech Stock Following Its $11 Billion Cancer Drug Agreement? - The Globe and Mail
BioNTech (BNTX) shares surged nearly 18.1% after announcing a partnership with Bristol-Myers Squibb (BMY) to develop its cancer immunotherapy, BNT327, in a deal worth up to $11.1 billion. Despite a wider net loss reported in Q1, analysts remain bullish, with Clear Street raising its price target for BNTX to $181, highlighting confidence in BioNTech's oncology pipeline.
Jun 3, 2025
Positive Outcomes: AstraZeneca, Pfizer, and Gilead unveil findings on cancer treatments - CNBC
At the American Society of Clinical Oncology meeting, AstraZeneca's Enhertu showed promise in treating HER2-positive breast cancer, while Pfizer's Braftovi improved survival in colorectal cancer. Gilead's Trodelvy and Merck's Keytruda combination also demonstrated effectiveness in breast cancer. However, Merck and Daiichi Sankyo withdrew their lung cancer drug patritumab deruxtecan after disappointing results. Amgen's Imdelltra showed positive outcomes in lung cancer, and Bristol Myers Squibb partnered with BioNTech for cancer immunotherapy development.
Jun 3, 2025
Kymera's Shares Rise Following Encouraging Results for Experimental Dermatitis Treatment - TradingView
Kymera Therapeutics, Inc. (KYMR) announced positive phase I clinical results for its investigational drug KT-621, showing comparable efficacy to Dupixent (dupilumab). The study demonstrated significant STAT6 degradation and a favorable safety profile. Shares of KYMR rose 7.2% year-to-date, and the company plans to accelerate KT-621's development for various Th2-related conditions. Data from further studies is expected in 2025 and 2026.
Jun 3, 2025
Traws Pharma Rises Sharply Following Promising Cancer Treatment Results: What’s Behind the Increase? - Raging Bull
Traws Pharma, Inc. (NASDAQ: TRAW) surged over 100% in pre-market trading following promising clinical trial results for its oncology drug rigosertib, showing an 80% response rate in patients with recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. The company is seeking partners for further development, while also advancing antiviral candidates like tivoxavir marboxil and ratutrelvir.
Jun 3, 2025
Kymera Rises Following Initial Protein Degrader Results - BioSpace
Kymera Therapeutics announced promising Phase I results for its protein degrader KT-621, showing over 90% degradation of the STAT6 protein in healthy volunteers. Analysts at Truist Securities liken it to an oral version of Sanofi and Regeneron's Dupixent, predicting significant sales potential. The drug, well-tolerated with a strong safety profile, is set for further trials in eczema, atopic dermatitis, and asthma.
Jun 3, 2025
ASCO25: Genmab's Rina-S shows promise for 'blockbuster potential' with new positive findings
Genmab's antibody drug conjugate, rinatabart sesutecan (Rina-S), achieved a 50% confirmed objective response rate in advanced endometrial cancer patients during the Phase I/II RAINFOL-01 trial. The drug's promising efficacy and safety data bolster investor confidence in its potential as a blockbuster treatment. Genmab plans to advance Rina-S into pivotal studies for various cancers, including ovarian and non-small cell lung cancer.
Jun 3, 2025
Wockhardt's Managing Director reports that a third of NHS prescriptions in the UK suggest medications produced in India.
Wockhardt's Managing Director, Ravi Limaye, highlighted that one in three NHS prescriptions in the UK recommends Indian-made drugs. He emphasized India's growth in generic pharmaceuticals and the sourcing of 60% of UK COVID-19 vaccines from Wockhardt. Limaye noted the company's potential antibiotic is nearing market readiness and urged Indian policymakers to enhance the business environment for further expansion in Europe and the US.
Jun 2, 2025
Vera Therapeutics Shares Surge Following Breakthrough Results from Kidney Disease Study - Raging Bull
Vera Therapeutics (NASDAQ: VERA) shares surged over 65% in pre-market trading following positive results from the Phase 3 ORIGIN trial for atacicept, a drug targeting IgA nephropathy. The trial demonstrated a 46% reduction in proteinuria, a key kidney damage marker. Vera plans to submit a Biologics License Application by Q4 2025, with potential market entry in 2026.
Jun 2, 2025
What factors are driving a 7.2% CAGR growth in the APAC Generic Drugs Market through 2034?
The Asia Pacific Generic Drugs Market is projected to grow from USD 48.70 billion in 2024 to USD 97.61 billion by 2034, with a CAGR of 7.2%. Key drivers include government support, patent expiries, and rising biosimilars. Major players like Teva Pharmaceutical Industries, Viatris, and Sun Pharmaceutical are expanding their presence in this growing sector.
Jun 2, 2025
Bristol Myers collaborates with BioNTech on a new cancer treatment - STAT News
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront for a 50% share in the experimental cancer drug BNT327, targeting PD-L1 and VEGF. Additional payments could reach $2 billion annually through 2028, with potential milestone payments of up to $7.6 billion. This partnership aims to enhance cancer treatment options amid competitive developments in the field.
Jun 2, 2025
Regeneron's combination weight-loss medication aids in muscle preservation, according to research - TradingView
Regeneron's experimental drug, trevogrumab, combined with Novo Nordisk's Wegovy, helped patients preserve up to 51% of lean mass while losing more fat in a mid-stage trial. The combination resulted in an 11.3% body weight loss compared to 10.4% with Wegovy alone. Regeneron also plans to license an obesity drug from Hansoh Pharmaceuticals in a $2.01 billion deal.
Jun 2, 2025
Gilead Shares Encouraging Results from Study Combining Trodelvy and Keytruda - The Globe and Mail
Gilead Sciences, Inc. announced positive results from the ASCENT-04/KEYNOTE-D19 study, showing that its breast cancer drug Trodelvy (sacituzumab govitecan-hziy) combined with Merck’s Keytruda reduced disease progression or death by 35% in patients with PD-L1+ metastatic triple-negative breast cancer. The study highlights Trodelvy's potential as a first-line treatment option. Gilead's shares have risen 20% this year.
Jun 2, 2025
Sanofi Enters into a $9.5 Billion Deal to Purchase Blueprint Medicines - TradingView
Sanofi (SNY) has agreed to acquire Blueprint Medicines (BPMC) for up to $9.5 billion, boosting its immunology portfolio with the addition of Ayvakit (avapritinib). The deal, expected to close in Q3 2025, includes a $129 per share cash payment and potential milestone payments. Ayvakit sales reached $149.4 million in Q1 2025, with projections of $2 billion by 2030.
Jun 2, 2025
Sanofi set to purchase Blueprint Medicines in a $9.5 billion agreement focused on rare diseases - Sharecafe
Sanofi has agreed to acquire Blueprint Medicines for up to $9.5 billion, enhancing its rare disease and immunology portfolio. The deal includes a $129 per share cash payment and potential milestone payments for BLU-808. Blueprint's Ayvakit (avapritinib) is the only approved therapy for systemic mastocytosis, with projected sales reaching $2 billion by 2030. The acquisition aims to strengthen Sanofi's pipeline amid recent setbacks.
Jun 2, 2025
FTC Takes Action Against Drug Patents That Limit Generic Market Competition
The Federal Trade Commission (FTC) is challenging over 200 disputed patents in the FDA’s Orange Book, claiming they block affordable generic medications for asthma, diabetes, and COPD. Companies like Novartis, Teva, and Mylan Specialty received warning letters. The FTC aims to enhance competition and reduce drug prices, following a recent court ruling against Teva's patent listings.
Jun 2, 2025
Kymera Therapeutics Claims Its Atopic Dermatitis Potential Rivals That of Sanofi/Regeneron...
Kymera Therapeutics, Inc. announced promising Phase 1 results for its oral STAT6 degrader, KT-621, showing robust STAT6 degradation and a favorable safety profile. The drug demonstrated rapid absorption and significant reductions in STAT6 levels, outperforming results from Sanofi and Regeneron's Dupixent study. The ongoing BroADen trial in atopic dermatitis patients is set to report data in Q4 2025.
Jun 2, 2025
Should You Consider Investing in Regeneron Pharmaceuticals Shares? - Trefis
Regeneron Pharmaceuticals (NASDAQ:REGN) shares plummeted 19% after its COPD treatment, itepekimab, failed a late-stage trial. The setback, coupled with declining sales of Eylea and FDA approval issues, has raised concerns. Despite this, analysts suggest REGN may be undervalued, with strong profitability and a promising pipeline, making it a potential buying opportunity for investors.
